258 related articles for article (PubMed ID: 15771919)
1. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Circulation; 2008 Jan; 117(4):494-502. PubMed ID: 18172039
[TBL] [Abstract][Full Text] [Related]
3. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin.
Seipelt IM; Crawford SE; Rodgers S; Backer C; Mavroudis C; Seipelt RG; Pahl E
J Heart Lung Transplant; 2004 Mar; 23(3):317-22. PubMed ID: 15019641
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
7. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
8. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
Marschang P; Sandhofer A; Ritsch A; Fiŝer I; Kvas E; Patsch JR
J Intern Med; 2006 Aug; 260(2):151-9. PubMed ID: 16882279
[TBL] [Abstract][Full Text] [Related]
9. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
16. Prevention of mortality from coronary heart disease with pravastatin.
Tonkin AM; Ryan EW
Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
[TBL] [Abstract][Full Text] [Related]
17. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
[TBL] [Abstract][Full Text] [Related]
18. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
